^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
EBV-specific anti-PD1 TCR-T cells
i
Other names: EBV-specific anti-PD1 TCR-T cells, EBV-specific TCR-T cell with anti-PD1 auto-secreted element
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
TCRCure
Drug class:
PD1 inhibitor
Related drugs:
1year
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov)
P1/2, N=18, Recruiting, Xinqiao Hospital of Chongqing | Trial completion date: Feb 2022 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Jan 2024
Trial completion date • Trial primary completion date
|
IL2 (Interleukin 2)
|
EBV-specific anti-PD1 TCR-T cells
Share via
